Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.
A single fatal case report documenting an unusual dual infection in CGD with a novel genetic mutation; raises clinical awareness but provides no comparative data or interventional evidence.
Well-designed mechanistic study with CRISPR screens and in vivo validation identifies MCT1 as a resistance mechanism to SMAD3 inhibition and demonstrates synergy in preclinical models, but lacks clinical evidence and human efficacy data.
Single-center retrospective cohort of 21 children describing clinical and genetic spectrum of rare immune dysregulation disorders; descriptive analysis without comparator or control group, providing phenotypic characterization rather than outcome evidence.
A controlled human infection model in older adults identifying age-related immune correlates of RSV protection, but a small single-centre study with exploratory endpoints that requires confirmation in vaccine trials.
Mechanistic mouse study showing β-glucan-induced trained immunity impairs lung CD8 Trm formation after RSV infection, but lacks clinical translation and comparator arm specificity.
A narrative review synthesizing 30 years of gene therapy evolution for inborn errors of immunity, tracing technological advances and identifying barriers to clinical translation, rather than presenting new primary evidence.
First-in-human Phase I/II trial with only 3 patients treated and 6-month follow-up data reported for one patient; early data suggest safety and potential efficacy but remain insufficient for definitive clinical guidance.